tbuckley/cabot-search huggingface dataset:
Solid lipid nanoparticle-based dissolving microneedles: A promising intradermal lymph targeting drug delivery system with potential for enhanced treatment of lymphatic filariasis
Authors: Andi Dian Permana, Ismaiel A. Tekko, Maelíosa T.C. McCrudden, Qonita Kurnia Anjani, Delly Ramadon, Helen O. McCarthy, Ryan F. Donnelly
Journal: Journal of Controlled Release (2019)

Conventional oral therapy of lymphatic filariasis drugs is only effective to kill microfilariae in the bloodstream, but is often ineffective to kill adult filarial (macrofilariae) in the complex anatomy of the lymphatic system. The encapsulation of drugs into lipid-based nanoparticles with sizes of <100nm, and administration intradermally, could be used to enhance lymphatic uptake. Therefore, we developed an innovative approach, using solid lipid nanoparticles (SLNs) and dissolving microneedles (MNs) to deliver antifilariasis drugs, namely doxycycline, diethylcarbamazine and albendazole, intradermally. The SLNs were prepared from Geleol® and Tween®80 as a lipid matrix and stabilizer, respectively. The formulations were optimized using a central composite design, producing SLNs with sizes of <100nm. Drug release was sustained over 48h from SLNs, compared to pure drugs. The SLNs were then incorporated into a polymeric hydrogel which was casted to form SLNs-loaded MNs. SLNs-loaded MNs exhibited sufficient mechanical and insertion properties. Importantly, dermatokinetic studies showed that>40% of drugs were retained in the dermis of excised neonatal porcine skin up to 24h post-MN application, indicating the high possibility of the SLNs to be taken by the lymphatic system. In in vivo studies, the maximal lymph concentrations of the three drugs in rat, achieved following intradermal delivery, ranged between 4- and 7-fold higher than that recorded after oral administration. Additionally, compared to oral administration, despite the lower plasma Cmax and organ-distribution, the AUC and relative bioavailability of the three drugs in rat plasma was also higher using our delivery approach. Accordingly, this delivery approach could maximize the drugs concentrations in the lymph system without essentially increasing their plasma concentrations. This could potentially deliver the drugs efficiently to the bloodstream, where the microfilariae reside, while also targeting drug to the lymph nodes, where filarial nematodes reside in infected patients, leading to an effective therapy for lymphatic filariasis.
RUNX3 and SHH in medulloblastoma
Authors: Bee Keow Peh, Kwan Min Lee Victor, Yoshiaki Ito, Manuel Salto-Tellez
Journal: Cancer Research (2008)

4310  Medulloblastoma is a highly malignant primary brain tumor that originates in the cerebellum. Morphologically, the presence of desmoplastic features. Desmoplastic Medulloblastoma (DMB, as opposed to the conventional type) is known to be associated with mutations of the sonic hedgehog (SHH) signaling pathway. Previously, we have reported RUNX3 overexpression in basal cell carcinoma (Oncogene 2006;25(58):7646-9), another SHH related disease model while, in general, RUNX3 is inactivated in most human cancers by protein mislocalization and promoter hypermethylation. Medulloblastoma clinical samples were screened for RUNX3 protein expression by immunohistochemistry. Western blot analysis was carried out on ATCC medulloblastoma cell lines (desmoplastic and conventional). Genomic DNA and total RNA was extracted from these cell lines. The genomic DNA was amplified by PCR and sequenced at the coding exons of RUNX3. Hypermethlyation of the RUNX3 promoter region was carried out. RUNX3 transcription was analysed by real-time PCR. The clinical DMB samples tested showed that RUNX3 protein is over-expressed in the nuclei of the cancer cells. This was concordant with the Western blot analysis of the desmoplastic medulloblastoma cell line, while the conventional cell line failed to show this overexpression. No mutation was detected in the coding exons of RUNX3 in these cell lines. Based on the immunohistochemistry staining, we have ruled out protein mislocalization for inactivation of RUNX3 in the conventional MB. Since promoter hypermethylation is a mechanism for gene and protein downregulation in other models, we explored the RUNX3 methylation in all the cell lines. While the cell lines showed unmethylated RUNX3 promoter region, the RUNX3 mRNA was actively transcribed. DMB is SHH related and, as in the BCC model, is associated with RUNX3 protein overexpression both in cell lines and clinical samples, a biological observation that may have important prognostic implications.
P2.01-66 Genomic Landscapes of DNA Copy Number Alterations in Primary Lung Cancers and Matched Brain Metastases
Authors: M. Nicoś, S. Garnerone, L. Harbers, A. Kowalczyk, A. Bożyk, R. Peksa, B. Jarosz, A. Perdyan, M. Sawicki, R. Duchnowska, J. Szumilo, W. Biernat, T. Trojanowski, J. Milanowski, P. Krawczyk, J. Jassem, N. Crosetto
Journal: Journal of Thoracic Oncology (2019)
P1.01-119 Modified Lung Immune Prognostic Index (mLIPI) as a Predictive Tool of Nivolumab Outcomes in Advanced NSCLC Patients
Authors: R. Moor, K. Roberts, R. Mason, R. Ladwa, Z. Lwin, B. Hughes, K. O'Byrne
Journal: Journal of Thoracic Oncology (2019)
P2.04-14 NLR, dNLR and PLR as Possible Predictive Markers in Patients with NSCLC Treated with ICI
Authors: S. Carnio, A. Mariniello, P. Pizzutilo, G. Numico, G. Borra, A. Lunghi, H. Soto Parra, R. Buosi, T. Vavalà, I. Stura, S. Genestroni, A. Alemanni, F. Arizio, A. Catino, M. Montrone, D. Galetta, G. Migliaretti, S. Novello
Journal: Journal of Thoracic Oncology (2019)
EP1.16-36 A Good Intestinal Bacterial Environment Can Reduce the Side Effects of Tyrosine Kinase Inhibitors and Enhance Their Anti-Cancer Effects
Authors: J. Shimada, S. Okada, H. Tsunezuka, M. Shimomura, S. Ishihara, M. Inoue, Y. Naito
Journal: Journal of Thoracic Oncology (2019)
Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions
Authors: Nan Chiang, Stephania Libreros, Paul C. Norris, Xavier de la Rosa, Charles N. Serhan
Journal: Journal of Clinical Investigation (2019)

Resolution of acute inflammation is an active process orchestrated by endogenous mediators and mechanisms pivotal in host defense and homeostasis. The macrophage mediator in resolving inflammation, maresin 1 (MaR1), is a potent immunoresolvent, stimulating resolution of acute inflammation and organ protection. Using an unbiased screening of greater than 200 GPCRs, we identified MaR1 as a stereoselective activator for human leucine-rich repeat containing G protein-coupled receptor 6 (LGR6), expressed in phagocytes. MaR1 specificity for recombinant human LGR6 activation was established using reporter cells expressing LGR6 and functional impedance sensing. MaR1-specific binding to LGR6 was confirmed using 3H-labeled MaR1. With human and mouse phagocytes, MaR1 (0.01-10 nM) enhanced phagocytosis, efferocytosis, and phosphorylation of a panel of proteins including the ERK and cAMP response element-binding protein. These MaR1 actions were significantly amplified with LGR6 overexpression and diminished by gene silencing in phagocytes. Thus, we provide evidence for MaR1 as an endogenous activator of human LGR6 and a novel role of LGR6 in stimulating MaR1's key proresolving functions of phagocytes.
MA10.11 Sensitivity and Optimal Clinicopathological Features of Genetic Targeted Liquid Biopsy in pN0M0 Lung Adenocarcinoma
Authors: M. Ito, Y. Miyata, S. Hirano, F. Irisuna, N. Kishi, Y. Tsutani, R. Rosell, M. Okada
Journal: Journal of Thoracic Oncology (2019)
P2.01-96 Response to Anti-HER2 Afatinib in a Case of Invasive Pulmonary Mucinous Adenocarcinoma with a SLC3A2-NRG1 Fusion
Authors: F. Magne, V. Haddad, L. Odier, M. Duruisseaux, S. Blandin, C. Dussopt, L. Falchero, D. Arpin
Journal: Journal of Thoracic Oncology (2019)
Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome
Authors: Jose Manuel Calvo-Villas, Eulogio Conde, Adriana Pascual, Inmaculada Heras, Rosario Varela, Javier de la Rubia, Maria José Ramirez, Rafael Carrión, Carlos Panizo, Alejandro Martín, Maria José Rodríguez-Salazar, Maria José Pascual, Eva Donato, Sara Nistal, Antonio Salar, Rafael Andreu, Juan-Manuel Sancho, Javier Briones, Reyes Arranz, José Nicolá S. Rodríguez, Emilia Pardal, M.a Soledad Duran, Francisco Javier Peñalver, Jose Antonio García-Marco, Rodolfo Mataix, Jose Antonio Queizán, Eva González-Barca, Dolores Caballero
Journal: Blood (2008)
P1.14-01 Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC?
Authors: O.F. Olmez, A. Bilici, P. Gursoy, E. Çubukçu, O. Yildiz, A. Sakin, T. Korkmaz, I. Cil, B. Cakar, S. Menekse, T. Demir, O. Acikgoz, J. Hamdard
Journal: Journal of Thoracic Oncology (2019)
JCSE01.20 Pilot Study on the Tumor Immune Microenvironment Between Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Authors: W. Zhang, X. Yuan, X. Wang, S. Huang, J. Tu, F. Liu, J. Li, J. Li, Y. Chen, Q. Chu
Journal: Journal of Thoracic Oncology (2019)
E-cigarette Use, or Vaping, Practices and Characteristics Among Persons with Associated Lung Injury — Utah, April–October 2019
Authors: Nathaniel Lewis, Keegan McCaffrey, Kylie Sage, Chia-Jung Cheng, Jordan Green, Leah Goldstein, Hillary Campbell, Deanna Ferrell, Nathan Malan, Nathan LaCross, Alejandra Maldonado, Amy Board, Arianna Hanchey, Dixie Harris, Sean Callahan, Scott Aberegg, Ilene Risk, Sarah Willardson, Amy Carter, Allyn Nakashima, Janae Duncan, Cindy Burnett, Robyn Atkinson-Dunn, Angela Dunn
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

In August 2019, the Utah Department of Health (UDOH) received reports from health care providers of several cases of lung injury in persons who reported use of electronic cigarette (e-cigarette), or vaping, products (1,2). To describe the characteristics of medical care, potentially related conditions, and exposures among 83 patients in Utah, detailed medical abstractions were completed for 79 (95%) patients. Among patients receiving chart abstractions, 70 (89%) were hospitalized, 39 (49%) required breathing assistance, and many reported preexisting respiratory and mental health conditions. Interviews were conducted by telephone or in person with 53 (64%) patients or their proxies, and product samples from eight (15%) of the interviewed patients or proxies were tested. Among 53 interviewed patients, all of whom reported using e-cigarette, or vaping, products within 3 months of acute lung injury, 49 (92%) reported using any products containing tetrohydrocannabinol (THC), the principal psychoactive component of cannabis; 35 (66%) reported using any nicotine-containing products, and 32 (60%) reported using both. As reported in Wisconsin and Illinois (1), most THC-containing products were acquired from informal sources such as friends or illicit in-person and online dealers. THC-containing products were most commonly used one to five times per day, whereas nicotine-containing products were most commonly used >25 times per day. Product sample testing at the Utah Public Health Laboratory (UPHL) showed evidence of vitamin E acetate in 17 of 20 (89%) THC-containing cartridges, which were provided by six of 53 interviewed patients. The cause or causes of this outbreak is currently unknown (2); however, the predominant use among patients of e-cigarette, or vaping, products with prefilled THC-containing cartridges suggests that the substances in these products or the way in which they are heated and aerosolized play an important role in the outbreak. At present, persons should not use e-cigarette, or vaping, products that contain THC. In addition, because the specific cause or causes of lung injury are not yet known and while the investigation continues, persons should consider refraining from use of all e-cigarette, or vaping, products.
P2.01-27 Apparent Diffusion Coefficient (ADC) Change on Repeated Diffusion-Weighted MRI During Chemotherapy for Stage IV Lung NSCLC
Authors: O. Grundberg, M. Skorpil, S. Swerkersson, K. Kölbeck, R. Karimi, L. De Petris
Journal: Journal of Thoracic Oncology (2019)
P1.14-34 The Landscape of MET Alterations in Chinese Non-Small Cell Lung Cancer Patients
Authors: M. Zheng, P. Jun, S. Wang, M. Li, N. Mao, Y. Liu, T. Cheng, H. Lan, J. Zhao, W. Wang, J. Hu, M. Yao, K. Wang, Y. Qu
Journal: Journal of Thoracic Oncology (2019)
JCSE01.23 Specific TP53 Mutation Subtypes as Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC
Authors: H. Sun, S. Liu, J.Y. Zhou, M. Zheng, J.J. Huan, Y.F. Guan, R. Gao, X. Yi, Y. Wu
Journal: Journal of Thoracic Oncology (2019)
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Authors: Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Tibor Csoszi, Gyula Ostoros, Zsuzsanna Mark, Christina Baik, Anil Abraham Joy, Christos Chouaid, Jesus Corral Jaime, Vitezslav Kolek, Margarita Majem, Jaromir Roubec, Edgardo S. Santos, Anne C. Chiang, Giovanna Speranza, Chandra P. Belani, Alberto Chiappori, Manish R. Patel, Krisztina Czebe, Lauren Byers, Brittany Bahamon, Cong Li, Emily Sheldon-Waniga, Eric F. Kong, Miguel Williams, Sunita Badola, Hyunjin Shin, Lisa Bedford, Jeffrey A. Ecsedy, Matthew Bryant, Sian Jones, John Simmons, E. Jane Leonard, Claudio Dansky Ullmann, David R. Spigel
Journal: Journal of Thoracic Oncology (2019)

We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC.In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant or refractory) and brain metastases and randomized 1:1 to alisertib/paclitaxel or placebo plus paclitaxel (henceforth referred to as placebo/paclitaxel) in 28-day cycles. The primary end point was progression-free survival (PFS). Associations of c-Myc expression in tumor tissue (prespecified) and genetic alterations in circulating tumor DNA (retrospective) with clinical outcome were evaluated.A total of 178 patients were enrolled (89 in each arm). The median PFS was 3.32 months with alisertib/paclitaxel versus 2.17 months with placebo/paclitaxel (hazard ratio [HR] = 0.77, 95% confidence limit [CI]: 0.557-1.067, p = 0.113 in the intent-to-treat population versus HR = 0.71, 95% CI: 0.509-0.985, p = 0.038 with corrected analysis applied). Among 140 patients with genetic alternations, patients with cell cycle regulator mutations (cyclin-dependent kinase 6 gene [CDK6], retinoblastoma-like 1 gene [RBL1], retinoblastoma-like 2 gene [RBL2], and retinoblastoma 1 gene [RB1]) had significantly improved PFS with alisertib/paclitaxel versus with placebo/paclitaxel (3.68 versus 1.80 months, respectively [HR = 0.395, 95% CI: 0.239-0.654, p = 0.0003]), and overall survival (7.20 versus 4.47 months, respectively [HR = 0.427, 95% CI: 0.259-0.704, p = 0.00085]). A subset of patients with c-Myc expression showed significantly improved PFS with alisertib/paclitaxel. The incidence of grade 3 or higher drug-related adverse events was 67% (58 patients) with alisertib/paclitaxel versus 22% (25 patients) with placebo/paclitaxel. Twelve patients (14%) versus 11 (12%) died on study, including four versus zero treatment-related deaths.Efficacy signals were seen with alisertib/paclitaxel in relapsed or refractory SCLC. c-Myc expression and mutations in cell cycle regulators may be potential predictive biomarkers of alisertib efficacy; further prospective validations are warranted.
MA07.03 A Circulating MicroRNAs-Based Test as Biomarker of Primary and Secondary Resistance in PD-L1 ≥50% NSCLC Treated with Immunotherapy
Authors: C. Proto, A. Prelaj, C. Verri, D. Signorelli, G. Lo Russo, R. Ferrara, G. Galli, B. Trevisan, M. Mensah, F. De Braud, M. Garassino, G. Sozzi, M. Boeri
Journal: Journal of Thoracic Oncology (2019)
EP1.04-06 Analysis of the Relationship Between Ratio N / L and Survival in Patients Treated with Immunotherapy in Lung Cancer
Authors: N. De Dios Alvarez, S. Agraso Busto, D. Pereiro, A. Alonso Herrero, M. Lazaro, G. Huidobro, J. Casal
Journal: Journal of Thoracic Oncology (2019)
EP1.01-10 Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Authors: N. Jahan, S. Swarup, A. Sultan, T. Naing, F. Mogollon-Duffo, S. Ball, A. Tun, T. Htut, A. Dash, N. D’Cunha, F. Hardwicke, S. Awasthi, L. Tijani, K. Thein
Journal: Journal of Thoracic Oncology (2019)
P2.18-10 Importance of the Multidisciplinary Tumor Board in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC)
Authors: J. Benet, A.C. Toffart, G. Frey, T. Chollier, S. Ruckly, J. Villa, C. Emprou, J. Pinsolle, I. Dumas, P. Guillem, G. Ferretti, D. Moro-Sibilot, M. Giaj Levra
Journal: Journal of Thoracic Oncology (2019)
OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial
Authors: N. Rizvi, B.C. Cho, N. Reinmuth, K.H. Lee, A. Luft, M. Ahn, V. Papadimitrakopoulou, J. Heymach, U. Scheuring, B. Higgs, J. Ye, M. Kuziora, S. Wu, F. Liu, H. Si, S. Peters
Journal: Journal of Thoracic Oncology (2019)
OA14.07 Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy
Authors: Y. Kim, C.H. Kim, S. Lee, H.Y. Lee, H.S. Kim, K. Kim, J. Sun, J.S. Ahn, M. Ahn, K. Park
Journal: Journal of Thoracic Oncology (2019)
More non-UK graduates than home grown clinicians joined medical register in past year
Authors: Adrian O’Dowd
Journal: BMJ (2019)

For the first time, last year the number of doctors joining the medical register who graduated outside the UK exceeded those who trained in the country, the General Medical Council has reported.1

Reliance on overseas clinicians to provide healthcare in the UK was made clear in a workforce report published by the regulator on 24 October that showed the workforce to be increasingly international, while UK medical graduates were more ethnically diverse than ever before.

The report also showed a sharper rise in the number of doctors on GP training programmes in the last year than in the previous six years.

Specifically focusing on workforce issues, the report was based on the GMC’s own midyear 2012 to 2019 workforce data from the UK medical registers. It also includes responses from 3876 doctors who completed an accompanying survey.

It shows that the number of doctors licensed …
DNA Repair Gene Expression in CD34+ Bone Marrow Cells in MDS Patients with Mutiple Chromosomal Abnormalities by Array-Based Comparative Genomic Hybridization (A-CGH).
Authors: Lukasz P. Gondek, Christine L. O’Keefe, Matt Kalaycio, Anjali Advani, Mikkael M. Sekeres, Jaroslaw P. Maciejewski
Journal: Blood (2005)
OA09.06 Residential Radon, Smoking and Lung Cancer Risk. A Case-Control Study in a Radon Prone Area
Authors: A. Ruano-Ravina, M. Lorenzo-González, M. Provencio, M. Torres-Durán, I. Parente-Lamelas, I. Vidal-García, J. Barros-Dios
Journal: Journal of Thoracic Oncology (2019)
Optimizing the Physician Workforce for Care of Patients With Type 2 Diabetes
Authors: Michael Pignone
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Underrepresentation of Women Among Authors of Invited Commentaries in Medical Journals—Where Are the Female Editorialists?
Authors: Elizabeth Loder, Rebecca Burch
Journal: JAMA Network Open (2019)

Emma G. Thomas, MSc, MA; Bamini Jayabalasingham, PhD; Tom Collins, PhD; Jeroen Geertzen, PhD; Chinh Bui, PhD; Francesca Dominici, PhD
P1.18-27 Chemoradiotherapy of Inoperable Non-Small Cell Lung Cancer (NSCLC) with IGRT Technique Using TomoTherapy HD
Authors: M. Zemanová, S. Hloušek, R. Jirásková, P. Zemanová, J. Končeková, B. Pejchalová, T. Kohlová, L. Petruželka
Journal: Journal of Thoracic Oncology (2019)
Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and persistence
Authors: Samreen Fatima, Shashank Shivaji Kamble, Ved Prakash Dwivedi, Debapriya Bhattacharya, Santosh Kumar, Anand Ranganathan, Luc Van Kaer, Sujata Mohanty, Gobardhan Das
Journal: Journal of Clinical Investigation (2019)

Tuberculosis (TB) remains a major infectious disease worldwide. TB treatment displays a biphasic bacterial clearance, in which the majority of bacteria clear within the first month of treatment, but residual bacteria remain nonresponsive to treatment and eventually may become resistant. Here, we have shown that Mycobacterium tuberculosis was taken up by mesenchymal stem cells (MSCs), where it established dormancy and became highly nonresponsive to isoniazid, a major constituent of directly observed treatment short course (DOTS). Dormant M. tuberculosis induced quiescence in MSCs and promoted their long-term survival. Unlike macrophages, where M. tuberculosis resides in early-phagosomal compartments, in MSCs the majority of bacilli were found in the cytosol, where they promoted rapid lipid synthesis, hiding within lipid droplets. Inhibition of lipid synthesis prevented dormancy and sensitized the organisms to isoniazid. Thus, we have established that M. tuberculosis gains dormancy in MSCs, which serve as a long-term natural reservoir of dormant M. tuberculosis. Interestingly, in the murine model of TB, induction of autophagy eliminated M. tuberculosis from MSCs, and consequently, the addition of rapamycin to an isoniazid treatment regimen successfully attained sterile clearance and prevented disease reactivation.
P2.06-07 Phase 1 Study of CA-170: First-in-Class Small Molecule Targeting VISTA/PD-L1 in Patients with Malignant Pleural Mesothelioma
Authors: M. Zauderer, J. Brody, T. Marron, S. Pacey, R. Martell, H. Wang, J. Spicer
Journal: Journal of Thoracic Oncology (2019)
P2.01-97 Angiotensin-Converting Enzyme Inhibitor Is Associated with Decreased Survival in NSCLC Patients Treated with PD-1 Checkpoint Blockers
Authors: S. Medjbar, C. Richard, J. Fumet, J. Malo, A. Elkrief, B. Routy, R. Boidot, C. Truntzer, F. Ghiringhelli
Journal: Journal of Thoracic Oncology (2019)
P1.03-45 Circulating Tumor Cells' Clearance in Blood Samples After Chemotherapy: A Good Prognostic Factor for OS in Advanced NSCLC
Authors: L. Milla Collado, C. Fraile Olivero, C. Cerdan Santacruz, T. Valverde Higueras, J.L. Gonzalez Larriba, I. Cal Vazquez, J. Jarabo Sarceda, E. Fernández Martín, F. Hernando-Trancho
Journal: Journal of Thoracic Oncology (2019)
P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy
Authors: G. Durm, S. Althouse, A. Sadiq, S. Jalal, S. Jabbour, R. Zon, G. Kloecker, M. Williamson, K. Reckamp, E. Kio, R. Langdon, B. Adesunloye, R. Gentzler, W. Harb, R. Walling, C. Yeon, M. Koczywas, N. Hanna
Journal: Journal of Thoracic Oncology (2019)